David A. Siegel Galectin Therapeutics Inc Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
Shares
3 transactions
Others Institutions Holding GALT
# of Institutions
75Shares Held
9.35MCall Options Held
982KPut Options Held
2.7K-
Vanguard Group Inc Valley Forge, PA2.12MShares$5.16 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$3.82 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.13MShares$2.75 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA842KShares$2.05 Million0.0% of portfolio
-
Commonwealth Equity Services, LLC483KShares$1.18 Million0.0% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $145M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...